Literature DB >> 31662545

Granulation Tissue-induced Pseudo-relapse During Nivolumab Treatment in Advanced Non-small Cell Lung Cancer.

Chihiro Ando1, Eiki Ichihara2, Hirohisa Kano3, Yoshitaka Iwamoto3, Atsuko Hirabae1, Takamasa Nakasuka3, Yoshinobu Maeda3, Katsuyuki Kiura1.   

Abstract

Atypical tumor responses such as pseudo-progression or hyper-progression sometimes occur during immune check point inhibitor therapy. Distinct from both responses, we experienced a case of non-small cell lung cancer (NSCLC) with a pseudo-relapse, in which development of granulation mimicked cancer relapse during nivolumab therapy. A male with advanced NSCLC started nivolumab as a second-line therapy. After 15 cycles of nivolumab with a complete response, tumor markers started increasing and positron-emission computed tomography indicated a hot spot in the sigmoid colon. Laparoscopic segmental sigmoid colon resection revealed granulation tissue without any relapse of malignant cells. The results showed that even if radiographical tumor progression is found during immune therapy, histological confirmation should be considered. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Lung cancer; granulation tissue; immune checkpoint inhibitors; nivolumab

Mesh:

Substances:

Year:  2019        PMID: 31662545      PMCID: PMC6899131          DOI: 10.21873/invivo.11711

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  8 in total

1.  EBUS-TBNA Can Distinguish Sarcoid-Like Side Effect of Nivolumab Treatment from Tumor Progression in Non-Small Cell Lung Cancer.

Authors:  Ségolène Lainez; Claire Tissot; Michèle Cottier; Jean-Michel Vergnon
Journal:  Respiration       Date:  2017-09-15       Impact factor: 3.580

2.  Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.

Authors:  Daichi Fujimoto; Hiroshige Yoshioka; Yuki Kataoka; Takeshi Morimoto; Tae Hata; Young Hak Kim; Keisuke Tomii; Tadashi Ishida; Masataka Hirabayashi; Satoshi Hara; Manabu Ishitoko; Yasushi Fukuda; Moon Hee Hwang; Naoki Sakai; Motonari Fukui; Hitoshi Nakaji; Mitsunori Morita; Tadashi Mio; Takehiro Yasuda; Takakazu Sugita; Toyohiro Hirai
Journal:  J Thorac Oncol       Date:  2018-11-20       Impact factor: 15.609

3.  Serum levels of CA-50, CA-19.9, CA-125, CA-15.3, enolase and carcino-embryonic antigen in non neoplastic diseases of the lung.

Authors:  F Marechal; G Berthiot; G Deltour
Journal:  Anticancer Res       Date:  1988 Jul-Aug       Impact factor: 2.480

Review 4.  Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors.

Authors:  Ioannis Gkiozos; Alexandra Kopitopoulou; Alexandros Kalkanis; Ioannis N Vamvakaris; Marc A Judson; Konstantinos N Syrigos
Journal:  J Thorac Oncol       Date:  2018-05-12       Impact factor: 15.609

5.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

6.  Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma.

Authors:  Mathew R Birnbaum; Michelle W Ma; Sarah Fleisig; Stuart Packer; Bijal D Amin; Mark Jacobson; Beth N McLellan
Journal:  JAAD Case Rep       Date:  2017-04-14

7.  Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment.

Authors:  Léa Paolini; Caroline Poli; Simon Blanchard; Thierry Urban; Anne Croué; Marie-Christine Rousselet; Sarah Le Roux; Nathalie Labarrière; Pascale Jeannin; José Hureaux
Journal:  J Immunother Cancer       Date:  2018-06-13       Impact factor: 13.751

8.  Sarcoid-Like Granulomatosis Induced by Nivolumab Treatment in a Lung Cancer Patient.

Authors:  Susumu Noguchi; Hiroaki Kawachi; Hiroshi Yoshida; Akari Fukao; Satoshi Terashita; Tatsuyoshi Ikeue; Sadao Horikawa; Takakazu Sugita
Journal:  Case Rep Oncol       Date:  2018-08-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.